Background: The risk of recurrent venous thrombosis is higher in men than in women, and
this is so far unexplained. We set out to determine the influence of age, time between first …

Arterial thrombosis and venous thromboembolism (VTE) are traditionally considered two
different entities. However, patients with unprovoked VTE are at higher risk of developing …

Background Prediction of recurrent venous thrombosis remains a challenge in the clinic.
Objective To investigate the predictive value of coagulation factor VIII (FVIII) levels for …

The potential role of the detection of residual thrombosis after deep vein thrombosis (DVT) in
the differentiation of patients at risk for recurrent venous thromboembolism (VTE) has not yet …

Background Antiphospholipid syndrome (APS) is an acquired thrombophilia disorder with
prevalence not completely known in patients with first unprovoked venous thromboembolic …

Introduction Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent
on the presence or absence of provoking risk factors at the time of the event. Objective To …

Objectives The study hypothesis was that a target‐specific anticoagulant would allow
successful home treatment of selected patients with deep vein thrombosis (DVT) and …

Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-
vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT …

Background In order to stratify patients with a first unprovoked venous thromboembolism
(VTE) according to their recurrence risk and to identify those who would actually benefit from …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …